738 related articles for article (PubMed ID: 31538520)
1. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
2. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
4. Fighting the resistance: rejuvenating anticancer platinum-based drugs.
O'Hare A
Nanomedicine (Lond); 2012 Jul; 7(7):947-8. PubMed ID: 23019670
[TBL] [Abstract][Full Text] [Related]
5. Lipid prodrug nanocarriers in cancer therapy.
Mura S; Bui DT; Couvreur P; Nicolas J
J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
[TBL] [Abstract][Full Text] [Related]
6. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
7. Dimeric prodrug-based nanomedicines for cancer therapy.
Li S; Shan X; Wang Y; Chen Q; Sun J; He Z; Sun B; Luo C
J Control Release; 2020 Oct; 326():510-522. PubMed ID: 32721523
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in prodrug-based nanoparticle therapeutics.
Chen KJ; Plaunt AJ; Leifer FG; Kang JY; Cipolla D
Eur J Pharm Biopharm; 2021 Aug; 165():219-243. PubMed ID: 33979661
[TBL] [Abstract][Full Text] [Related]
9. Quantitative and high drug loading of self-assembled prodrug with defined molecular structures for effective cancer therapy.
Tang J; Zeng Z; Yan J; Chen C; Liu J; Feng X
J Control Release; 2019 Aug; 307():90-97. PubMed ID: 31185233
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable and pH-Responsive Acetalated Dextran (Ac-Dex) Nanoparticles for NIR Imaging and Controlled Delivery of a Platinum-Based Prodrug into Cancer Cells.
Braga CB; Perli G; Becher TB; Ornelas C
Mol Pharm; 2019 May; 16(5):2083-2094. PubMed ID: 30901218
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
12. Chitosan derivatives functionalized dual ROS-responsive nanocarriers to enhance synergistic oxidation-chemotherapy.
Liao JX; Huang QF; Li YH; Zhang DW; Wang GH
Carbohydr Polym; 2022 Apr; 282():119087. PubMed ID: 35123755
[TBL] [Abstract][Full Text] [Related]
13. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
14. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
[TBL] [Abstract][Full Text] [Related]
15. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
Sun N; Zhao C; Cheng R; Liu Z; Li X; Lu A; Tian Z; Yang Z
Mol Pharm; 2018 Aug; 15(8):3343-3355. PubMed ID: 29923726
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
17. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
Yu HP; Aljuffali IA; Fang JY
Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
[TBL] [Abstract][Full Text] [Related]
18. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
[TBL] [Abstract][Full Text] [Related]
19. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.
Hayashi JY; Tamanoi F
Enzymes; 2017; 42():153-172. PubMed ID: 29054269
[TBL] [Abstract][Full Text] [Related]
20. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
